ADVERTISEMENT

COVID-19: nirmatrelvir/ritonavir oral treatment reduces death and severe illness

Jenny Blair, MD   |   Clinical Summary   |   10 June 2022
ADVERTISEMENT

Takeaway

  • Among high-risk vaccinated patients with COVID-19, nirmatrelvir/ritonavir substantially reduces risk for death or severe disease in the real world.
  • Adequate vaccination status is even more protective.

Why this matters

  • Nirmatrelvir/ritonavir received emergency use authorization based on interim analysis of the EPIC-HR trial, which was conducted before the Omicron era....

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right